<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/255"/><api:result><api:object category="publication" id="255" last-affected-when="2024-03-16T19:34:10.007+00:00" last-modified-when="2024-03-16T19:34:10.007+00:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/255" created-when="2010-05-17T13:46:14.617+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>1999-08-26</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="1449608" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1097/00001813-199903000-00005" last-modified-when="2022-09-11T20:29:57.583+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Groener</api:last-name><api:initials>MGH</api:initials><api:first-names>MGH</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>G</api:first-name><api:first-name>H</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>van Ineveld</api:last-name><api:initials>BM</api:initials><api:first-names>BM</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2594" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2594"/></api:links><api:last-name>van Hout</api:last-name><api:initials>BA</api:initials><api:first-names>BA</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Rutten</api:last-name><api:initials>FFH</api:initials><api:first-names>FFH</api:first-names><api:separate-first-names><api:first-name>F</api:first-name><api:first-name>F</api:first-name><api:first-name>H</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1097/00001813-199903000-00005</api:text><api:links><api:link type="doi" href="http://doi.org/10.1097/00001813-199903000-00005"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1097/00001813-199903000-00005"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0959-4973</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972924"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Anti-Cancer Drugs</api:text></api:field><api:field name="language" type="text" display-name="Language"><api:text>en</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>283</api:begin-page><api:end-page>288</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Ovid Technologies (Wolters Kluwer Health)</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1097/00001813-199903000-00005</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>10</api:day><api:month>11</api:month><api:year>2021</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>10</api:text></api:field></api:native></api:record><api:record format="native" id="131394" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0032796814" last-modified-when="2021-06-09T19:01:05.557+01:00"><api:citation-count>16</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Our objective was to establish the balance between costs and effects of treatment with Tomudex (raltitrexed) as an alternative to treatment with 5-fluorouracil (5-FU) plus leucovorin (LV) in patients with advanced colorectal cancer. Data were used from an international, open label randomized clinical trial. Costs were calculated by multiplying resource utilization data with Dutch estimates of unit costs. Effects have been expressed in terms of 6 months and 1 year survival, and in terms of the number of patients without severe adverse events including WHO grade 3 and 4 leucopenia, mucositis, anemia and severe asthenia. Cost effectiveness is expressed in terms of costs per additional day of survival and costs per additional patient without any severe adverse event. The clinical results did not show significant survival differences implying great uncertainty about the cost-effectiveness of raltitrexed in terms of additional costs per additional life-year gained. However, 80% of the initially higher cost of raltitrexed ($3132 per patient) is compensated by savings due to a more convenient administration scheme leading to a net cost of $626 per patient treated. Weighed against the decrease in adverse events, a cost-effectiveness ratio results of $3936 per additional patient free of any severe adverse event. More favorable estimates result when the convenience of the administration scheme is valued in positive monetary terms.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Groener</api:last-name><api:initials>MGH</api:initials><api:first-names>MGH</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>G</api:first-name><api:first-name>H</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="organisation">Erasmus Universiteit Rotterdam</api:line><api:line type="city">Rotterdam</api:line><api:line type="country">Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6507599266</api:identifier></api:identifiers></api:person><api:person><api:last-name>Van Ineveld</api:last-name><api:initials>BM</api:initials><api:first-names>BM</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="organisation">Erasmus Universiteit Rotterdam</api:line><api:line type="city">Rotterdam</api:line><api:line type="country">Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">6603369524</api:identifier></api:identifiers></api:person><api:person><api:last-name>Byttebier</api:last-name><api:initials>G</api:initials><api:first-names>G</api:first-names><api:separate-first-names><api:first-name>G</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="BE"><api:line type="organisation">ZENECA NV</api:line><api:line type="city">Destelbergen</api:line><api:line type="country">Belgium</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">57223998150</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="2594" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2594"/></api:links><api:last-name>Van Hout</api:last-name><api:initials>BA</api:initials><api:first-names>BA</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="organisation">Erasmus Universiteit Rotterdam</api:line><api:line type="city">Rotterdam</api:line><api:line type="country">Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">57191081993</api:identifier></api:identifiers></api:person><api:person><api:last-name>Rutten</api:last-name><api:initials>FFH</api:initials><api:first-names>FFH</api:first-names><api:separate-first-names><api:first-name>F</api:first-name><api:first-name>F</api:first-name><api:first-name>H</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="organisation">Erasmus Universiteit Rotterdam</api:line><api:line type="city">Rotterdam</api:line><api:line type="country">Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7005090997</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1097/00001813-199903000-00005</api:text><api:links><api:link type="doi" href="http://doi.org/10.1097/00001813-199903000-00005"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1097/00001813-199903000-00005"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10327033</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0959-4973</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972924"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Anti-Cancer Drugs</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>283</api:begin-page><api:end-page>288</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>26</api:day><api:month>8</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>10</api:text></api:field></api:native></api:record><api:record format="native" id="255" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10327033" last-modified-when="2020-04-29T04:09:08.04+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Our objective was to establish the balance between costs and effects of treatment with Tomudex (raltitrexed) as an alternative to treatment with 5-fluorouracil (5-FU) plus leucovorin (LV) in patients with advanced colorectal cancer. Data were used from an international, open label randomized clinical trial. Costs were calculated by multiplying resource utilization data with Dutch estimates of unit costs. Effects have been expressed in terms of 6 months and 1 year survival, and in terms of the number of patients without severe adverse events including WHO grade 3 and 4 leucopenia, mucositis, anemia and severe asthenia. Cost effectiveness is expressed in terms of costs per additional day of survival and costs per additional patient without any severe adverse event. The clinical results did not show significant survival differences implying great uncertainty about the cost-effectiveness of raltitrexed in terms of additional costs per additional life-year gained. However, 80% of the initially higher cost of raltitrexed ($3132 per patient) is compensated by savings due to a more convenient administration scheme leading to a net cost of $626 per patient treated. Weighed against the decrease in adverse events, a cost-effectiveness ratio results of $3936 per additional patient free of any severe adverse event. More favorable estimates result when the convenience of the administration scheme is valued in positive monetary terms.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Groener</api:last-name><api:initials>MG</api:initials><api:first-names>MG</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>G</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="full">Erasmus University Rotterdam, Institute for Medical Technology Assessment, The Netherlands. mirande.groener@ridderkerk.zeneca.com</api:line></api:address></api:addresses><api:email-address>mirande.groener@ridderkerk.zeneca.com</api:email-address></api:person><api:person><api:last-name>van Ineveld</api:last-name><api:initials>BM</api:initials><api:first-names>BM</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Byttebier</api:last-name><api:initials>G</api:initials><api:first-names>G</api:first-names><api:separate-first-names><api:first-name>G</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2594" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2594"/></api:links><api:last-name>van Hout</api:last-name><api:initials>BA</api:initials><api:first-names>BA</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Rutten</api:last-name><api:initials>FF</api:initials><api:first-names>FF</api:first-names><api:separate-first-names><api:first-name>F</api:first-name><api:first-name>F</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10327033</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1097/00001813-199903000-00005</api:text><api:links><api:link type="doi" href="http://doi.org/10.1097/00001813-199903000-00005"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1097/00001813-199903000-00005"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0959-4973</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972924"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Anticancer Drugs</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh">Colorectal Neoplasms</api:keyword><api:keyword scheme="mesh">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh">Costs and Cost Analysis</api:keyword><api:keyword scheme="mesh">Fluorouracil</api:keyword><api:keyword scheme="mesh">Health Care Costs</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Leucovorin</api:keyword><api:keyword scheme="mesh">Netherlands</api:keyword><api:keyword scheme="mesh">Quinazolines</api:keyword><api:keyword scheme="mesh">Randomized Controlled Trials as Topic</api:keyword><api:keyword scheme="mesh">Survival Analysis</api:keyword><api:keyword scheme="mesh">Thiophenes</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>England</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>283</api:begin-page><api:end-page>288</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>29</api:day><api:month>6</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Clinical Trial</api:item><api:item>Journal Article</api:item><api:item>Randomized Controlled Trial</api:item><api:item>Research Support, Non-U.S. Gov't</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>10</api:text></api:field></api:native></api:record><api:record format="native" id="873009" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10327033" last-modified-when="2020-11-25T00:07:21.18+00:00"><api:citation-count>7</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>Our objective was to establish the balance between costs and effects of treatment with Tomudex (raltitrexed) as an alternative to treatment with 5-fluorouracil (5-FU) plus leucovorin (LV) in patients with advanced colorectal cancer. Data were used from an international, open label randomized clinical trial. Costs were calculated by multiplying resource utilization data with Dutch estimates of unit costs. Effects have been expressed in terms of 6 months and 1 year survival, and in terms of the number of patients without severe adverse events including WHO grade 3 and 4 leucopenia, mucositis, anemia and severe asthenia. Cost effectiveness is expressed in terms of costs per additional day of survival and costs per additional patient without any severe adverse event. The clinical results did not show significant survival differences implying great uncertainty about the cost-effectiveness of raltitrexed in terms of additional costs per additional life-year gained. However, 80% of the initially higher cost of raltitrexed ($3132 per patient) is compensated by savings due to a more convenient administration scheme leading to a net cost of $626 per patient treated. Weighed against the decrease in adverse events, a cost-effectiveness ratio results of $3936 per additional patient free of any severe adverse event. More favorable estimates result when the convenience of the administration scheme is valued in positive monetary terms.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="NL"><api:line type="full">Erasmus University Rotterdam, Institute for Medical Technology Assessment, The Netherlands. mirande.groener@ridderkerk.zeneca.com</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Groener</api:last-name><api:initials>MG</api:initials><api:first-names>MG</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>G</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>van Ineveld</api:last-name><api:initials>BM</api:initials><api:first-names>BM</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Byttebier</api:last-name><api:initials>G</api:initials><api:first-names>G</api:first-names><api:separate-first-names><api:first-name>G</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2594" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2594"/></api:links><api:last-name>van Hout</api:last-name><api:initials>BA</api:initials><api:first-names>BA</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Rutten</api:last-name><api:initials>FF</api:initials><api:first-names>FF</api:first-names><api:separate-first-names><api:first-name>F</api:first-name><api:first-name>F</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1097/00001813-199903000-00005</api:text><api:links><api:link type="doi" href="http://doi.org/10.1097/00001813-199903000-00005"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1097/00001813-199903000-00005"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1473-5741</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972924"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10327033</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0959-4973</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972924"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Anti-cancer drugs</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Colorectal Neoplasms</api:keyword><api:keyword scheme="mesh">Fluorouracil</api:keyword><api:keyword scheme="mesh">Thiophenes</api:keyword><api:keyword scheme="mesh">Leucovorin</api:keyword><api:keyword scheme="mesh">Quinazolines</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh">Survival Analysis</api:keyword><api:keyword scheme="mesh">Costs and Cost Analysis</api:keyword><api:keyword scheme="mesh">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh">Health Care Costs</api:keyword><api:keyword scheme="mesh">Netherlands</api:keyword><api:keyword scheme="mesh">Randomized Controlled Trials as Topic</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>283</api:begin-page><api:end-page>288</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>18</api:day><api:month>5</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Clinical Trial</api:item><api:item>Research Support, Non-U.S. Gov't</api:item><api:item>Randomized Controlled Trial</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>10</api:text></api:field></api:native></api:record><api:record format="native" id="2739642" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1046951910" last-modified-when="2024-03-16T19:34:10.01+00:00"><api:citation-count>13</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Groener</api:last-name><api:initials>MG</api:initials><api:first-names>MG</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>G</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="NL"><api:line type="organisation">Erasmus University Rotterdam</api:line><api:line type="city">Rotterdam</api:line><api:line type="country">Netherlands</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0707520470.86</api:identifier></api:identifiers></api:person><api:person><api:last-name>van Ineveld</api:last-name><api:initials>BM</api:initials><api:first-names>BM</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01050525350.68</api:identifier></api:identifiers></api:person><api:person><api:last-name>Byttebier</api:last-name><api:initials>G</api:initials><api:first-names>G</api:first-names><api:separate-first-names><api:first-name>G</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01037507113.19</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="2594" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2594"/></api:links><api:last-name>van Hout</api:last-name><api:initials>BA</api:initials><api:first-names>BA</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01167771713.07</api:identifier></api:identifiers></api:person><api:person><api:last-name>Rutten</api:last-name><api:initials>FF</api:initials><api:first-names>FF</api:first-names><api:separate-first-names><api:first-name>F</api:first-name><api:first-name>F</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01174260760.93</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1097/00001813-199903000-00005</api:text><api:links><api:link type="doi" href="http://doi.org/10.1097/00001813-199903000-00005"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1097/00001813-199903000-00005"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10327033</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0959-4973</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972924"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Anti-Cancer Drugs</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3202 Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc">Patient Safety</api:keyword><api:keyword scheme="rcdc">Digestive Diseases</api:keyword><api:keyword scheme="rcdc">Cancer</api:keyword><api:keyword scheme="rcdc">Clinical Trials and Supportive Activities</api:keyword><api:keyword scheme="rcdc">Cost Effectiveness Research</api:keyword><api:keyword scheme="rcdc">Clinical Research</api:keyword><api:keyword scheme="rcdc">Colo-Rectal Cancer</api:keyword><api:keyword scheme="rcdc">Comparative Effectiveness Research</api:keyword><api:keyword scheme="hrcs-rac">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-rac">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac">8 Health and social care services research</api:keyword><api:keyword scheme="hrcs-rac">8.2 Health and welfare economics</api:keyword><api:keyword scheme="hrcs-hc">Cancer</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh">Colorectal Neoplasms</api:keyword><api:keyword scheme="mesh">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh">Costs and Cost Analysis</api:keyword><api:keyword scheme="mesh">Fluorouracil</api:keyword><api:keyword scheme="mesh">Health Care Costs</api:keyword><api:keyword scheme="mesh">Humans</api:keyword><api:keyword scheme="mesh">Leucovorin</api:keyword><api:keyword scheme="mesh">Netherlands</api:keyword><api:keyword scheme="mesh">Quinazolines</api:keyword><api:keyword scheme="mesh">Randomized Controlled Trials as Topic</api:keyword><api:keyword scheme="mesh">Survival Analysis</api:keyword><api:keyword scheme="mesh">Thiophenes</api:keyword></api:keywords></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>283</api:begin-page><api:end-page>288</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Wolters Kluwer</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>0.36</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>10</api:text></api:field></api:native></api:record><api:record format="native" id="240152" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000080345700005" last-modified-when="2024-03-14T05:33:10.723+00:00"><api:citation-count>14</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Groener</api:last-name><api:initials>MGH</api:initials><api:first-names>MGH</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>G</api:first-name><api:first-name>H</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>van Ineveld</api:last-name><api:initials>BM</api:initials><api:first-names>BM</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Byttebier</api:last-name><api:initials>G</api:initials><api:first-names>G</api:first-names><api:separate-first-names><api:first-name>G</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2594" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2594"/></api:links><api:last-name>van Hout</api:last-name><api:initials>BA</api:initials><api:first-names>BA</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Rutten</api:last-name><api:initials>FFH</api:initials><api:first-names>FFH</api:first-names><api:separate-first-names><api:first-name>F</api:first-name><api:first-name>F</api:first-name><api:first-name>H</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000080345700005&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1097/00001813-199903000-00005</api:text><api:links><api:link type="doi" href="http://doi.org/10.1097/00001813-199903000-00005"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1097/00001813-199903000-00005"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">197BX</api:identifier><api:identifier scheme="pubmed">10327033</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0959-4973</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972924"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>ANTI-CANCER DRUGS</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>advanced colorectal cancer</api:keyword><api:keyword>chemotherapy</api:keyword><api:keyword>economic evaluation</api:keyword><api:keyword>palliation</api:keyword><api:keyword>thymidylate synthase inhibitor</api:keyword><api:keyword>Tomudex</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>283</api:begin-page><api:end-page>288</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>1999</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>10</api:text></api:field></api:native></api:record><api:record format="native" id="22812" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000080345700005" last-modified-when="2014-07-25T11:01:50.663+01:00"><api:citation-count>11</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Groener</api:last-name><api:initials>MGH</api:initials><api:first-names>MGH</api:first-names><api:separate-first-names><api:first-name>M</api:first-name><api:first-name>G</api:first-name><api:first-name>H</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>van Ineveld</api:last-name><api:initials>BM</api:initials><api:first-names>BM</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Byttebier</api:last-name><api:initials>G</api:initials><api:first-names>G</api:first-names><api:separate-first-names><api:first-name>G</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2594" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2594"/></api:links><api:last-name>van Hout</api:last-name><api:initials>BA</api:initials><api:first-names>BA</api:first-names><api:separate-first-names><api:first-name>B</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Rutten</api:last-name><api:initials>FFH</api:initials><api:first-names>FFH</api:first-names><api:separate-first-names><api:first-name>F</api:first-name><api:first-name>F</api:first-name><api:first-name>H</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0959-4973</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972924"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>3</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>ANTI-CANCER DRUG</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>advanced colorectal cancer</api:keyword><api:keyword>chemotherapy</api:keyword><api:keyword>economic evaluation</api:keyword><api:keyword>palliation</api:keyword><api:keyword>thymidylate synthase inhibitor</api:keyword><api:keyword>Tomudex</api:keyword><api:keyword>BIOCHEMICAL MODULATION</api:keyword><api:keyword>FLUOROURACIL</api:keyword><api:keyword>TRIAL</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>283</api:begin-page><api:end-page>288</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>3</api:month><api:year>1999</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>10</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Colorectal Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Costs and Cost Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Fluorouracil</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Health Care Costs</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Leucovorin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Netherlands</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Quinazolines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Randomized Controlled Trials as Topic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Survival Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Thiophenes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Colorectal Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Fluorouracil</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Thiophenes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Leucovorin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Quinazolines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Survival Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Costs and Cost Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Health Care Costs</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Netherlands</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Randomized Controlled Trials as Topic</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3202 Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3211 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Patient Safety</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Digestive Diseases</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Trials and Supportive Activities</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Cost Effectiveness Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Clinical Research</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Colo-Rectal Cancer</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Comparative Effectiveness Research</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6 Evaluation of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">6.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">8 Health and social care services research</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">8.2 Health and welfare economics</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antineoplastic Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Colorectal Neoplasms</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Cost-Benefit Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Costs and Cost Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Fluorouracil</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Health Care Costs</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Humans</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Leucovorin</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Netherlands</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Quinazolines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Randomized Controlled Trials as Topic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Survival Analysis</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Thiophenes</api:keyword><api:keyword origin="record-data" source="wos-lite">advanced colorectal cancer</api:keyword><api:keyword origin="record-data" source="wos-lite">chemotherapy</api:keyword><api:keyword origin="record-data" source="wos-lite">economic evaluation</api:keyword><api:keyword origin="record-data" source="wos-lite">palliation</api:keyword><api:keyword origin="record-data" source="wos-lite">thymidylate synthase inhibitor</api:keyword><api:keyword origin="record-data" source="wos-lite">Tomudex</api:keyword><api:keyword origin="record-data" source="wos">advanced colorectal cancer</api:keyword><api:keyword origin="record-data" source="wos">chemotherapy</api:keyword><api:keyword origin="record-data" source="wos">economic evaluation</api:keyword><api:keyword origin="record-data" source="wos">palliation</api:keyword><api:keyword origin="record-data" source="wos">thymidylate synthase inhibitor</api:keyword><api:keyword origin="record-data" source="wos">Tomudex</api:keyword><api:keyword origin="record-data" source="wos">BIOCHEMICAL MODULATION</api:keyword><api:keyword origin="record-data" source="wos">FLUOROURACIL</api:keyword><api:keyword origin="record-data" source="wos">TRIAL</api:keyword><api:keyword scheme="for" origin="issn-inferred">0304 Medicinal and Biomolecular Chemistry</api:keyword><api:keyword scheme="for" origin="issn-inferred">1101 Medical Biochemistry and Metabolomics</api:keyword><api:keyword scheme="for" origin="issn-inferred">1115 Pharmacology and Pharmaceutical Sciences</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3214 Pharmacology and pharmaceutical sciences</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3404 Medicinal and biomolecular chemistry</api:keyword></api:keywords></api:all-labels><api:journal issn="0959-4973" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/972924" title="Anti-Cancer Drugs"><api:records><api:record source-name="summary"><api:title>Anti-Cancer Drugs</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/255/relationships"/></api:object></api:result></api:response>